How should bisphosphonate-induced osteonecrosis of the jaw be treated?

Treatment of Bisphosphonate-Induced Osteonecrosis of the Jaw

Patients with suspected or established bisphosphonate-related osteonecrosis of the jaw (BRONJ) should be referred immediately to a dental practitioner or oral maxillofacial surgeon with expertise in treating this condition, with treatment stratified by disease stage using conservative management for early stages and surgical intervention for advanced disease. 1, 2

Initial Assessment and Referral

When BRONJ is suspected, refer the patient to a dental specialist experienced in managing this condition. The diagnosis requires exposed necrotic bone or fistulas probing to bone that persist for more than 8 weeks in patients with bisphosphonate exposure and no history of radiation therapy to the jaw 2, 3.

Stage-Based Treatment Algorithm

Stage 0 (At Risk/Increased Risk)

• No exposed bone but nonspecific symptoms or radiographic changes
• Symptomatic management with pain medication
• Patient education on oral hygiene and risk factor modification
• Clinical follow-up every 8 weeks with communication to oncologist
• No active treatment indicated 2

Stage 1 (Exposed Bone, No Infection)

• Antibacterial mouth rinses (chlorhexidine 0.12%)
• Clinical follow-up every 8-12 weeks
• Patient education on meticulous oral hygiene
• Avoid elective dental procedures
• Conservative approach is preferred - surgical intervention only if conservative measures fail 2, 3

Stage 2 (Exposed Bone with Infection)

• Antibacterial mouth rinses plus systemic antibiotics
• Pain control with analgesics
• Minimally invasive surgical debridement to remove loose sequestra and smooth sharp bone edges causing soft tissue irritation
• For oral bisphosphonate-related ONJ: Conservative treatment with minimally invasive surgery plus adjuvant therapies shows best outcomes 3
• For IV bisphosphonate-related ONJ: Conservative treatment with minimally invasive surgery (without adjuvant therapies) is most effective 3
• Continue antibiotics as needed for infection control 2

Stage 3 (Extensive Disease)

• More aggressive surgical approach with debridement or resection may be necessary
• Pain control and infection management with antibiotics
• Superficial, well-defined sequestra should be removed if atraumatic
• Consider biopsy of removed bone to rule out malignancy 2
• Surgical resection with antibiotic therapy shows better outcomes than conservative management alone in advanced stages 4, 5

Key Management Principles

Antibiotic Selection: Use antibiotics with bone penetration (penicillins, clindamycin, or fluoroquinolones) for infected cases. Duration should be based on clinical response 2.

Surgical Considerations:

• Remove symptomatic teeth within exposed necrotic bone - extraction is unlikely to worsen established necrosis 2
• Avoid elective dentoalveolar surgery in all BRONJ patients
• Early surgical intervention with complete sequestrum removal may provide better outcomes and decreased morbidity compared to prolonged conservative management 4

Bisphosphonate Discontinuation Decision

There is insufficient evidence to mandate bisphosphonate discontinuation in patients with BRONJ 2. The decision to defer BMA administration should be made jointly by the treating physician, patient, and oral health provider, weighing:

• The underlying indication for bisphosphonate therapy (cancer with bone metastases vs. osteoporosis)
• Risk of skeletal-related events if therapy is stopped
• Stage and severity of ONJ
• Patient's overall prognosis and life expectancy

For cancer patients requiring ongoing bone protection, the benefits of continued therapy may outweigh risks 2. For osteoporosis patients, temporary discontinuation during active ONJ treatment is more reasonable.

Critical Pitfalls to Avoid

• Do not perform elective dental extractions or implant placement in patients with established BRONJ - this creates additional sites of bone exposure
• Do not delay referral to an experienced oral surgeon - early specialist involvement improves outcomes
• Do not assume all exposed bone requires aggressive resection - conservative management succeeds in early stages 3, 5
• Do not forget calcium and vitamin D supplementation - hypocalcemia can complicate healing

Monitoring and Follow-up

Patients should be monitored every 8-12 weeks with clinical examination and communication between the dental specialist, oncologist, and primary care physician 2. Long-term follow-up is essential as healing may take months to years, with some patients requiring 6+ years of monitoring 4.